Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
This is the first major brand refresh of CanSinoBIO since its inception in 2009
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Subscribe To Our Newsletter & Stay Updated
